[EN]
Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and development of new drug candidates targeting G Protein-Coupled Receptors(GPCRs), one of the most important classes of drug targets. With teams at work in France and Canada, Domain operates multiple technologies aimed at validating targets and discovering first-in-class therapies (small molecules or antibodies). It creates a pipeline of high-value programs in immuno-oncology, neurology and rare diseases which are developed as proprietary programs up to early clinical phases or in collaboration with pharma partners.
[FR]
Domain Therapeutics est une société biopharmaceutique dédiée à la découverte et au développement de nouveaux candidats médicaments ciblant les récepteurs couplés aux protéines G (GPCR), l'une des classes de cibles médicamenteuses les plus importantes. Avec des équipes basées en France et au Canada, Domain exploite de multiples technologies visant à valider des cibles et à découvrir des thérapies de premier ordre (petites molécules ou anticorps), crée un pipeline de programmes de forte valeur ajoutée en immuno-oncologie, neurologie et maladies rares, développés seuls jusqu'aux premières phases cliniques ou en collaboration avec des partenaires pharmaceutiques.
Location: France, Grand Est, Illkirch-Graffenstaden
Employees: 51-200
Phone: +33 3 90 40 61 52
Total raised: $55.27M
Founded date: 2008
Investors 5
Date | Name | Website |
- | Auriga Par... | auriga.vc |
- | Capital Gr... | capitalgra... |
12.05.2022 | Turenne Ca... | turennecap... |
- | 3B Future ... | 3bfuturehe... |
- | Panacea Ve... | panaceaven... |
Funding Rounds 5
Date | Series | Amount | Investors |
23.05.2022 | Series A | $42M | adMare Bio... |
13.01.2020 | - | $6.68M | - |
28.05.2019 | - | $3.91M | - |
14.04.2014 | Grant | $230K | - |
17.07.2012 | - | $2.45M | - |
Mentions in press and media 11
Date | Title | Description | Source |
28.07.2023 | Latest Updates of 7 Viva's Portfolio Companies | HONG KONG, July 28, 2023 /PRNewswire/ -- In the face of ever-changing circumstances, technological i... | en.prnasia... |
27.07.2022 | Portfolio Highlights: Clinical and Financing Updates of AIxp... | SHANGHAI, China, July 27, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioI... | en.prnasia... |
26.05.2022 | Portfolio Highlights: Clinical and Financing Updates of Anji... | SHANGHAI, May 26, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator... | en.prnasia... |
10.05.2022 | Domain Therapeutics Raises $42M in Series A Financing | Domain Therapeutics, a Strasbourg, France- and Montreal, Canada-based biopharmaceutical company spec... | finsmes.co... |
10.05.2022 | adMare BioInnovations joins a $42m Series A financing in Dom... | Strasbourg, France – Montreal, Canada – May 10, 2022 – Domain Therapeutics, a biopharmaceutical comp... | admarebio.... |
08.06.2020 | Find Therapeutics, a new drug development company dedicated ... | The new company raises initial capital to develop transmembrane peptides against GPCRs to address hi... | admarebio.... |
13.01.2020 | Domain Therapeutics Secures €6M in Debt Financing | Domain Therapeutics, a Strasbourg, France-based biopharmaceutical company, closed a €6m ($6.7M) debt... | finsmes.co... |
28.05.2019 | Domain Therapeutics Raises €3.5M in Funding | Domain Therapeutics, a Strasbourg, France-based biopharma company, secured €3.5M ($3.9M) in funding.... | finsmes.co... |
28.05.2019 | Term Sheet — Tuesday May 28 | A TALE OF MANY MANY MERGERS Hello again, Term Sheet readers! I hope y’all had a grill-filled Memori... | fortune.co... |
14.04.2014 | Domain Therapeutics Receives $230K Second Grant from Michael... | Domain Therapeutics, a Strasbourg, France- and Montreal, Canada-based biopharmaceutical company dedi... | finsmes.co... |
Show more